Date: 2012-01-17
Type of information: R&D agreement
Compound: chimeric VLPs (virus-like particles), containing proteins of different serotypes on one VLP.
Company: Redbiotec (Switzerland) DKFZ - German Cancer Research Center (Germany)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism:
Disease: HPV (human papillomavirus) infections
Details: The German Cancer Research Institute (DKFZ) and Redbiotec have extended their collaboration in the field of HPV, which started in 2009. Goal of the collaboration is the validation of chimeric VLPs (virus-like particles), containing proteins of different serotypes on one VLP.
Financial terms:
Latest news:
